腺病毒介导的人喉癌p53基因治疗
[Adenovirus-mediated p53 gene therapy of human laryngeal cancer].
作者信息
Wang Q, Han D, Wang W
机构信息
Beijing Institute of Otolaryngology.
出版信息
Zhonghua Zhong Liu Za Zhi. 1998 Nov;20(6):418-21.
OBJECTIVE
To explore the potential use of p53 in gene therapy for laryngeal cancer.
METHODS
A human laryngeal cancer cell line Hep-2 was used. Recombinant cytomegalovirus-promoted adeno-viruses containing human wild-type p53 cDNA was transiently introduced into Hep-2 cells in vitro and injected into tumor nodules in vivo. The growth of Hep-2 cells in vitro and established s.c. squamous carcinoma nodules in nude mice was examined.
RESULTS
The transduction efficiency of Hep-2 cell line was 100% at > or = 100 MOI. The p53 protein expression peaked on day 2 after infection and lasted far 5 days. Cell growth was greatly suppressed. In vivo studies, Ad5CMV-p53 transfestion in vitro inhibited tumorigenicity of Hep-2 cells in nude mice. Intra-tumoral injection of Ad5CMV-p53 significantly inhibited established s.c. implanted xenograft.
CONCLUSION
Transfection of wild-type p53 gene via Ad5CMV-p53 is a potential approach to the therapy of laryngeal cancer.
目的
探讨p53在喉癌基因治疗中的潜在应用。
方法
使用人喉癌细胞系Hep-2。将含有人类野生型p53 cDNA的重组巨细胞病毒启动腺病毒体外瞬时导入Hep-2细胞，并体内注射到肿瘤结节中。检测Hep-2细胞在体外的生长情况以及在裸鼠体内建立的皮下鳞状癌结节情况。
结果
当感染复数（MOI）≥100时，Hep-2细胞系的转导效率为100%。p53蛋白表达在感染后第2天达到峰值，并持续5天。细胞生长受到极大抑制。在体内研究中，体外Ad5CMV-p53转染抑制了Hep-2细胞在裸鼠体内的致瘤性。瘤内注射Ad5CMV-p53显著抑制了已建立的皮下移植瘤。
结论
通过Ad5CMV-p53转染野生型p53基因是喉癌治疗的一种潜在方法。
Zotero 插件